PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW126600View Pathway |
Cannabinoid BiosynthesisCannabis sativa
Hexanoate is first catalyzed to make hexanoyl-CoA with the enzyme hexanoyl CoA synthase in the cytosol and within the membrane of the cell. Hexanoyl-CoA branches paths to olivetol biosynthesis which creates the byproducts of this pathway. The other pathway is catalyzed by olivetol synthase to make 3,5-dioxodecanoyl-CoA which is catalyzed to make 3,5,7-trioxododecanoyl-CoA. This is similar to the olivetol biosynthesis pathway, however here 3,5,7-trioxododecanoyl-CoA is catalyzed by olivetolic acid cyclase to make olivetolate. This takes place in the cytoplasm. Olivetolate along with geranyl diphosphate is catalyzed by olivetolate geranyltransferase to make cannabigerolate or cannabigerolic acid.
This compound branches into three separate pathways each catalyzed by a different enzymes. One pathway is catalyzed by Δ9-tetrahydrocannabinolate synthase along with oxygen to make Δ9-tetrahydrocannabinolate. This compound spontaneously reacts with hydrogen to synthesize the drug Δ9-tetrahydrocannabinol (THC). The second pathway is catalyzed by cannabidiolate synthase and oxygen to make cannabidiolate or cannabidiolic acid. Cannabidiolate spontaneously reacts with hydrogen to synthesize the drug cannabidiol (CBD). The final pathway is catalyzed by cannabichromenate synthase along with an unknown oxidized electron carrier to make cannabichromenate or cannabichromenic acid. This, like the others, spontaneously reacts with hydrogen to synthesize the drug cannabichromene (CBC).
|
Creator: Ray Kruger Created On: January 24, 2022 at 16:30 Last Updated: January 24, 2022 at 16:30 |
PW145945View Pathway |
drug action
Cannabidiol Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:02 Last Updated: October 07, 2023 at 17:02 |
PW124429View Pathway |
Cannabidiol and delta9-THC BiosynthesisCannabis sativa
|
Creator: Eponine Oler Created On: January 11, 2021 at 10:13 Last Updated: January 11, 2021 at 10:13 |
PW145715View Pathway |
drug action
Cangrelor Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:27 Last Updated: October 07, 2023 at 16:27 |
PW132563View Pathway |
Cangrelor Drug MetabolismHomo sapiens
Cangrelor is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Cangrelor passes through the liver and is then excreted from the body mainly through the kidney.
|
Creator: Ray Kruger Created On: September 21, 2023 at 22:25 Last Updated: September 21, 2023 at 22:25 |
PW122421View Pathway |
drug action
Cangrelor Action PathwayHomo sapiens
Cangrelor, marketed as Kengreal or Kengrexal, is an antiplatelet drug that targets the P2Y12 receptor of platelets. It was developed as a derivative of ATP that is not enzymatically degraded by the cell.
Cangrelor is already active, and is injected intravenously. Here, it binds to the P2Y purinoreceptor 12 on the surface of platelet cells, preventing ADP from binding to and activating it. Cangrelor prevents the activation of the Gi protein associated with the P2Y12 receptor from inactivating adenylate cyclase in the platelet, leading to a buildup of cAMP. This cAMP then activates calcium efflux pumps, preventing calcium buildup in the platelet, which would cause activation, and later, aggregation.
|
Creator: Eponine Oler Created On: March 29, 2019 at 15:49 Last Updated: March 29, 2019 at 15:49 |
PW127405View Pathway |
drug action
CandoxatrilHomo sapiens
Candoxatril is the prodrug of candoxatrilat that is activated via oral consumption, it is also a neutral endopeptidase inhibitor. It inhibits the metalloprotease enzymes, neutral endopeptidase and angiotensin-converting enzyme; inhibiting these enzymes increases peptides that act to induce vasodilation.
|
Creator: Selena Created On: January 08, 2023 at 11:53 Last Updated: January 08, 2023 at 11:53 |
PW145240View Pathway |
drug action
Candicidin Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:23 Last Updated: October 07, 2023 at 15:23 |
PW127403View Pathway |
drug action
Candicidin Action PathwayHomo sapiens
Candicidin is a polyene antifungal antibiotic produced by a strain of Streptomyces griseus. It is especially effective against Candida albicans (more effective than amphotericin B), and is administered intravaginally in the treatment of vulvovaginal candidiasis. Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of Candicidin. Candicidin binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death.
|
Creator: Ray Kruger Created On: January 05, 2023 at 15:47 Last Updated: January 05, 2023 at 15:47 |
PW175988View Pathway |
Candesartan cilexetil Predicted Metabolism Pathway newHomo sapiens
Metabolites of Candesartan cilexetil are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 13:02 Last Updated: November 29, 2023 at 13:02 |